Bowman & Co S.C. Has $429,000 Holdings in DexCom, Inc. (NASDAQ:DXCM)

Bowman & Co S.C. trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 17.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,519 shares of the medical device company’s stock after selling 1,158 shares during the period. Bowman & Co S.C.’s holdings in DexCom were worth $429,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. Blue Whale Capital LLP grew its position in shares of DexCom by 91.9% in the 3rd quarter. Blue Whale Capital LLP now owns 236,000 shares of the medical device company’s stock valued at $15,821,000 after purchasing an additional 113,000 shares during the period. Taylor Frigon Capital Management LLC lifted its stake in DexCom by 51.6% in the third quarter. Taylor Frigon Capital Management LLC now owns 32,554 shares of the medical device company’s stock valued at $2,182,000 after buying an additional 11,075 shares in the last quarter. Brooktree Capital Management acquired a new position in shares of DexCom in the third quarter valued at approximately $683,000. National Pension Service increased its position in shares of DexCom by 4.1% during the third quarter. National Pension Service now owns 949,743 shares of the medical device company’s stock worth $63,671,000 after acquiring an additional 37,363 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in shares of DexCom during the third quarter worth $650,000. 97.75% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently weighed in on DXCM shares. StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, November 2nd. Leerink Partners reduced their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Raymond James decreased their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Wells Fargo & Company boosted their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada decreased their price target on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Five research analysts have rated the stock with a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

Insider Activity

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.30% of the company’s stock.

DexCom Trading Down 0.5 %

Shares of NASDAQ:DXCM opened at $84.38 on Friday. The company has a 50-day simple moving average of $78.17 and a 200 day simple moving average of $77.98. The company has a market capitalization of $32.96 billion, a P/E ratio of 50.53, a price-to-earnings-growth ratio of 2.00 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.